Tagged with Santen

Saudi Arabia Mohamed Ayad, representing Santen as the Head of the Middle East, discusses the Japanese multinational firm’s growing presence and strategic focus in the region. He shares insights into the challenges and opportunities within the eye health care and ophthalmology market, Santen’s innovative approach to product offerings, and the company’s commitment…

Japan Santen is on a mission to reshape the future of eye health. With three major product launches ahead, bold biotech deals, and a revamped global strategy, the Japanese pharma is doubling down on its ophthalmology dominance. Fresh off a transformational reorganization and a landmark myopia approval, Santen is proving that…

China Eye health, despite being essential for most of us in our daily lives, receives significantly less research funding than fields like cancer or diabetes. According to IQVIA, global spending on oncology is expected to reach USD 440 billion by 2028, while ophthalmology will see just USD 38 billion. However, conditions…

China Shawn Xiang, corporate officer and China head at Santen, discusses the eye care specialist’s second-largest market and the challenges of diagnosing and managing eye conditions in China where a lack of public awareness is coupled with the country’s shortage of clinical capacity in ophthalmology. He remarks on Santen’s “China 2.0”…

Switzerland Marianthi Psaha, President, Head of EMEA for Santen, discusses the company’s journey towards becoming a specialized leader in ophthalmology—highlighting how digital transformation, innovation in myopia treatment, and strategic partnerships are reshaping its impact on eye health across Europe. Psaha delves into the challenges of building awareness of the area’s importance…

Switzerland Santen is a leading multinational company that specializes in ophthalmology. President and Head for Europe, Middle East and Africa (EMEA) Luis Iglesias highlights the company’s recent transformation through partnerships across a vast array of areas including digital technology and cell and gene. He also discusses how Santen has leveraged its…

USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…

USA Tatsuya Kaihara, head of US operations for Japanese eyecare specialist Santen, describes his excitement at bringing two new ophthalmic advancements to the US market, the similarities, differences, and synergies of Japanese and American innovation, and the challenges of building a unified corporate culture.   This is a very exciting moment…

China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…

China Japanese ophthalmology specialist Santen first established a China affiliate in 2005 and has grown very successfully in the past 14 years. GM of Santen Pharmaceutical (China) Co., Ltd. (hereafter, Santen China) Takayuki Yamada gives his first impressions of the Chinese market since his arrival in April 2019, Santen’s commitment to…

UK Craig Wallace established the UK affiliate of Santen, the Japanese ophthalmology company, in 2014. Wallace describes the journey Santen has been on so far in the UK, as well as his ambitions to contribute to its goal of becoming a leading global ophthalmology company by 2020.  You set up Santen’s…

Baltics Boriss Birmans, country manager of Santen Latvia, discusses the company’s focus on patient-centricity in the country, its ambition to bring in more preservative-free drugs for glaucoma patients and how its market share in Latvia is one of the highest in the entire EU. Can you walk us through Santen’s history…